Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?

Corcept Therapeutics (CORT) shares have surged 39.6% year-to-date, outperforming the industry, driven by significant progress with its lead pipeline candidate, relacorilant. The FDA has accepted relacorilant's NDA for Cushing's syndrome with a decision expected by December 30, 2025, and Corcept also submitted an NDA for the drug in platinum-resistant ovarian cancer following positive Phase III data. Despite this pipeline advancement, the company lowered its 2025 revenue guidance to $850-$900 million due to slower sales of its sole marketed product, Korlym, leading to recent decreases in 2025 and 2026 EPS estimates and highlighting a critical dependence on relacorilant's successful approval for future growth.

Analysis

Corcept Therapeutics (CORT) presents a classic high-reward, high-risk biotech investment profile, characterized by a significant stock appreciation that is disconnected from its current operational performance. Shares have surged 39.6% year-to-date, substantially outperforming the industry's 10.2% rise, driven almost entirely by optimism surrounding its lead pipeline candidate, relacorilant. The company has achieved critical regulatory milestones, including the FDA's acceptance of a New Drug Application (NDA) for relacorilant in Cushing's syndrome with a PDUFA target date of December 30, 2025, and the submission of a second NDA for its use in platinum-resistant ovarian cancer following positive phase III ROSELLA data. These potential approvals are pivotal, as they represent the sole path to diversifying revenue away from its only marketed product, Korlym. However, the company's fundamental picture is deteriorating. Management recently lowered its full-year 2025 revenue guidance to a range of $850-$900 million due to slowing sales of Korlym. This weakness is further reflected in downward consensus EPS estimate revisions for both 2025 and 2026. The valuation is stretched, with a price-to-sales ratio of 11.83, far exceeding the industry average of 2.42, indicating that successful, on-time approvals for relacorilant are already priced in, leaving the stock highly vulnerable to any regulatory or pipeline setbacks.

Key Decisions for Investors

• Investors should recognize CORT's current valuation reflects a high-stakes bet on the FDA's approval of relacorilant, with the December 30, 2025 PDUFA date for Cushing's syndrome being a pivotal catalyst.
• Monitor the company's sole dependence on its existing drug, Korlym, as its slowing sales, which prompted a lowered 2025 revenue forecast and downward EPS revisions, represent a significant fundamental risk.
• Given the stock's 39.6% year-to-date rally and premium valuation, it may be prudent to protect gains, as the current price leaves little margin for error against potential regulatory delays or negative data from ongoing studies.